for oral use Initial U.S. Approval: 2020
Tucatinib tablets is a “used to treat advanced, unresectable or metastatic HER2-positive breast cancer“. TUKYSA Tablets is a “prescription medicine. It is available in “form and strength” Tablets: 50 mg and 150 mg.. TUKYSA Tablets can be obtained in India upon request.
To inquire about the “offer price in India”, “shipping process”, and the “estimated time of availability in India”, please get in touch at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj). with the IPN Delhi healthcare team for further discussion.”
Facts about your medicine
Active substance: tucatinib
Disease Indications-Breast Cancer
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Swissmedic CH)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For Tucatinib Tablets
Know about product usage and updates
To access tucatinib tablets sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)
Who is the supplier of Specialty drug in India?
Indian Pharma Network (IPN) Legitimate consultant and facilitator for Specialty drugs in India. IPN, Delhi can assist you in connecting with prospective distributors, wholesalers, suppliers, and dealers of TUKYSA (tucatinib) tablets. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
TUKYSA (tucatinib) tablets, for oral use Initial U.S. Approval: 2020
Related posts for product review usage
- HIGHLIGHTS OF PRESCRIBING INFORMATION
- Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
- FDA Grants Accelerated Approval to Tucatinib Combination for Patients with HER2-Positive Metastatic Colorectal Cancer
- FDA Approves Zanubrutinib for First-line R/R CLL/SLL
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa